drugset
Drugs / BNT327
last change Sep 2025 re-read 3 minutes ago

BNT327

Other / unclassified

Developed for
breast carcinoma · cancer · female breast carcinoma · lung cancer · neoplasm · non-small cell lung carcinoma · small cell lung carcinoma · triple-negative breast carcinoma
Investigated by
BioNTech SE · DualityBio Inc. · BioNTech (Shanghai) Pharmaceuticals Co., Ltd. · Bristol-Myers Squibb · MediLink Therapeutics (Suzhou) Co., Ltd.

Trials 7

today NCT07111520 · Ph 1/2 NCT06953089 · Ph 2 NCT06892548 · Ph 1/2 NCT06827236 · Ph 1/2 NCT06449222 · Ph 2 NCT06449209 · Ph 2 NCT05438329 · Ph 1/2
20232024202520262027202820292030
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/24 trials
Phase 1/2 NCT07111520 Sep 2025 → Jan 2029 expected non-small cell lung carcinoma BioNTech SE Recruiting No outcome recorded
Phase 1/2 NCT06892548 May 2025 → Sep 2028 expected lung cancer BioNTech SE Recruiting No outcome recorded
Phase 1/2 NCT06827236 Apr 2025 → Aug 2029 expected breast carcinoma BioNTech SE Recruiting No outcome recorded
Phase 1/2 NCT05438329 Jul 2022 → Aug 2027 expected neoplasm DualityBio Inc. Active not recruiting No outcome recorded
Phase 23 trials
Phase 2 NCT06953089 Jul 2025 → Jun 2030 expected cancer DualityBio Inc. Recruiting No outcome recorded
Phase 2 NCT06449222 Aug 2024 → Aug 2028 expected female breast carcinoma, triple-negative breast carcinoma BioNTech SE Active not recruiting No outcome recorded
Phase 2 NCT06449209 Aug 2024 → Jun 2027 expected small cell lung carcinoma BioNTech SE Active not recruiting No outcome recorded

Press releases naming this drug 4 releases

DateIssuerRelease
2025-09-08 BioNTech SE First Disclosure of Global Interim Phase 2 Data for BioNTech and Bristol Myers Squibb PD-L1xVEGF-A Bispecific Antibody Pumitamig (BNT327/BMS986545) in Patients with Extensive-Stage Small Cell Lung Cancer Shows Encouraging Antitumor Activity biontech.com ↗
2025-09-08 Bristol-Myers Squibb First Disclosure of Global Interim Phase 2 Data for BioNTech and Bristol Myers Squibb PD-L1xVEGF-A Bispecific Antibody Pumitamig (BNT327/BMS986545) in Patients with Extensive-Stage Small Cell Lung Cancer Shows Encouraging Antitumor Activity bms.com ↗
2025-06-02 BioNTech SE BioNTech and Bristol Myers Squibb Announce Global Strategic Partnership to Co-Develop and Co-Commercialize Next-generation Bispecific Antibody Candidate BNT327 Broadly for Multiple Solid Tumor Types biontech.com ↗
2025-06-02 Bristol-Myers Squibb BioNTech and Bristol Myers Squibb Announce Global Strategic Partnership to Co-Develop and Co-Commercialize Next-generation Bispecific Antibody Candidate BNT327 Broadly for Multiple Solid Tumor Types bms.com ↗

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 7 sources stand behind the page.

FieldValueCited text
Known as BNT327 ClinicalTrials.gov intervention name — accepted as the source's own label NCT06953089 ↗
6

NCT06449222 ↗

NCT05438329 ↗

NCT06827236 ↗

NCT06449209 ↗

NCT06892548 ↗

NCT07111520 ↗
Modality Other / unclassified “BNT327, a programmed death-ligand 1 (PD-L1) and vascular endothelial growth factor (VEGF) bispecific antibody” NCT06892548 ↗
Route Intravenous “Administered I.V.” NCT05438329 ↗